UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study
2012 (English)In: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 250, no 1, 95-102 p.Article in journal (Refereed) Published
The aim of this work as to investigate the photochemical interaction used in corneal crosslinking (CXL) as the primary therapy for bacterial keratitis. less thanbrgreater than less thanbrgreater thanA prospective non-randomized study was conducted including 16 patients with a clinical diagnosis of bacterial keratitis. No patient had any prior antibiotic treatment for the current infection. Photography and microbial culturing of the infected cornea were performed. Riboflavin was topically administered for 20 min and ultraviolet light (UVA) exposure settings for treatment of keratoconus were used. After the procedure, clinical examinations were done at least once daily until signs of improvement had been established. The frequency of examinations was thereafter reduced. Antibiotic therapy was initiated if infectious progression was suspected. The trial was registered at ISCRTN.org (no: 21432643). less thanbrgreater than less thanbrgreater thanAll eyes responded to the photochemical treatment with improvement in symptoms and signs of reduced inflammation. Epithelial healing was achieved in all cases. Antibiotic administration was necessary in two cases. One patient required a human amniotic membrane transplant. less thanbrgreater than less thanbrgreater thanThis trial illustrates that photosensitization of riboflavin using UVA at 365 nm has the potential to induce healing in patients with microbial keratitis. The results from the treatment of these 16 patients with corneal ulcers indicate that UVA-riboflavin photochemical therapy merits a controlled study in order to assess its efficacy and safety compared to antibiotics.
Place, publisher, year, edition, pages
Springer Verlag (Germany) , 2012. Vol. 250, no 1, 95-102 p.
UV, UVA, Ultraviolet, Riboflavin, CXL, Keratitis, Pilot study
National CategoryMedical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-75115DOI: 10.1007/s00417-011-1754-1ISI: 000299371000012OAI: oai:DiVA.org:liu-75115DiVA: diva2:504544
Funding Agencies|Orebro University Hospital (Sweden)|OLL-57221|Futurum, the Academy of Health Care, Jonkoping (Sweden)||2012-02-212012-02-172012-02-21